<DOC>
	<DOCNO>NCT01352338</DOCNO>
	<brief_summary>Study Phase : phase 1 phase 2 Objective : Evaluation effect lenalidomide , cyclophophamide prednisone ( REP ) patient relapse multiple myeloma previously treat lenalidomide Study design : prospective , multicenter , non-randomized</brief_summary>
	<brief_title>Revlimid , Endoxan , Prednison Evaluation After Prior Revlimid Treatment ( REPEAT )</brief_title>
	<detailed_description>The REPEAT-study prospective , multicenter , non-randomized phase 1 phase 2 study evaluate effect lenalidomide , cyclophosphamide prednisone ( REP-therapy ) patient relapse multiple myeloma , previously treat lenalidomide refractory lenalidomide monotherapy .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>salmon &amp; Durie stage II/III A B previous lenalidomide refractory disease patient commits pregnancy prevention programme nonsecretory myeloma know hypersensitivity lenalidomide inadequate marrow reserve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>REPEAT</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>revlimid</keyword>
	<keyword>lenalidomide</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>endoxan</keyword>
	<keyword>prednisone</keyword>
	<keyword>lenalidomide refractory</keyword>
</DOC>